CVRx (CVRX)
(Delayed Data from NSDQ)
$9.22 USD
+0.74 (8.73%)
Updated May 3, 2024 04:00 PM ET
After-Market: $9.21 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.22 USD
+0.74 (8.73%)
Updated May 3, 2024 04:00 PM ET
After-Market: $9.21 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Zacks News
CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits
by Zacks Equity Research
CVRx's (CVRX) announcement of the availability of additional data supporting the long-term benefits of Barostim is likely to lead to improved patient care.
New Strong Buy Stocks for January 30th
by Zacks Equity Research
HCC, EGO, WRLD, PBPB and CVRX have been added to the Zacks Rank #1 (Strong Buy) List on January 30, 2024.
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of 20% and 3.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
CVRx (CVRX) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
CVRx (CVRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes CVRx (CVRX) a Good Fit for 'Trend Investing'
by Zacks Equity Research
CVRx (CVRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Take the Zacks Approach to Beat the Market: Boeing, McDonald's, Monster Beverage in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
AngioDynamics (ANGO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 44.44% and 3.15%, respectively, for the quarter ended November 2023. Do the numbers hold clues to what lies ahead for the stock?
CVRx (CVRX) Moves 24.2% Higher: Will This Strength Last?
by Zacks Equity Research
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why 'Trend' Investors Would Love Betting on CVRx (CVRX)
by Zacks Equity Research
CVRx (CVRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
CVRx (CVRX) Is Up 10.17% in One Week: What You Should Know
by Zacks Equity Research
Does CVRx (CVRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
CVRx (CVRX) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
CVRx (CVRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
CVRx (CVRX) Moves 7.1% Higher: Will This Strength Last?
by Zacks Equity Research
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Corbus Pharmaceuticals (CRBP) and CVRx (CVRX) have performed compared to their sector so far this year.
Recent Price Trend in CVRx (CVRX) is Your Friend, Here's Why
by Zacks Equity Research
CVRx (CVRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
CVRx (CVRX) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
CVRx (CVRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
What Makes CVRx (CVRX) a New Strong Buy Stock
by Zacks Equity Research
CVRx (CVRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of 24.56% and 6.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
CVRx (CVRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of 1.75% and 10.94%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
CVRx (CVRX) Surges 7.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
CVRx (CVRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
How Much Upside is Left in CVRx (CVRX)? Wall Street Analysts Think 25.09%
by Zacks Equity Research
The consensus price target hints at a 25.1% upside potential for CVRx (CVRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Should You Buy CVRx (CVRX) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of 3.51% and 9.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of 7.27% and 5.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of 14.29% and 5.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical (SWAV) Stock Jumps 6%: Will It Continue to Soar?
by Zacks Equity Research
Shockwave Medical (SWAV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.